8570 documents

Read All
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
Read More
17:44 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

ViiV planning submissions this year for two-drug HIV regimen

ViiV said it plans to submit regulatory applications this year for a once-monthly two-drug regimen comprising cabotegravir and Johnson & Johnson's Edurant rilpivirine to treat HIV-1 infection. ViiV Healthcare Ltd. (Brentford, U.K.) disclosed its plans...
Read More
17:36 , Mar 8, 2019 |  BC Week In Review  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions on March 1, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first...
Read More
19:12 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting soluble epoxide hydrolase for renal damage

DISEASE CATEGORY: Renal INDICATION: Renal damage Mouse studies suggest inhibiting soluble epoxide hydrolase could help treat renal damage. In a mouse model of diet-induced renal injury, a soluble epoxide hydrolase inhibitor tool compound decreased renal...
Read More
01:10 , Mar 2, 2019 |  BioCentury  |  Product Development

Roche broadens its BD scope

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on...
Read More
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
Read More
22:10 , Mar 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions Friday, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first approved antidote...
Read More
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology; inflammation

INDICATION: Stroke; shock/trauma Patient and mouse studies suggest inhibiting CCR5 could help treat stroke and traumatic brain injury (TBI). In stroke patients, the absence of a loss-of-function mutant CCR5 allele was associated with the severity...
Read More
23:56 , Feb 26, 2019 |  BC Extra  |  Company News

Management tracks: Immunomedics, Daiichi, Notable Labs

Immunomedics Inc. (NASDAQ:IMMU) said Michael Pehl resigned as president, CEO and a board member due to personal reasons, just 15 months after he joined the antibody-drug conjugate company. The news comes a month after FDA...
Read More
21:58 , Feb 21, 2019 |  BC Extra  |  Preclinical News

Repurposing an HIV target could aid brain injury recovery

Extending CCR5 inhibition beyond treating HIV/AIDS, UCLA researchers showed that blocking CCR5 could promote recovery from stroke and traumatic brain injury (TBI). CC chemokine receptor 5 (CCR5; CD195) is well known for its role in...
Read More